Actively Recruiting
Phase 1 Study of Tislelizumab and Pamiparib with Chemoradiotherapy for Recurrent Head and Neck Squamous Cell Carcinoma
Led by University of Chicago · Updated on 2026-03-04
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and highest safe dose of combining tislelizumab with pamiparib and chemoradiotherapy in people whose head and neck cancer has returned after previous treatment. This phase 1 trial focuses on patients with recurrent head and neck squamous cell carcinoma, aiming to find a dose that balances effectiveness and side effects while studying this combination treatment. Participants first receive one dose of tislelizumab, an experimental anti-cancer drug given intravenously. Then, they undergo chemoradiotherapy over five weeks, which includes chemotherapy drugs 5-FU and hydroxyurea, radiation therapy twice daily for five days, and daily doses of pamiparib, another experimental drug. Different doses of pamiparib are tested to find the best tolerated amount. After a rest period, participants receive monthly tislelizumab infusions for 12 months. The study includes a dose escalation phase followed by a dose expansion phase to further assess the chosen doses. During the study, participants are regularly monitored through clinic visits and various assessments to track safety, side effects, and cancer progression. Follow-up visits continue every four months for two years, then every six months for another two years, and yearly thereafter for life. Researchers measure outcomes including the maximum tolerated dose of pamiparib combined with other treatments, progression-free survival, and overall survival during the 15-month treatment period and beyond.
CONDITIONS
Brief Title
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Research Team
C
Cancer Trial Intake
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here